BO
Blue Owl Healthcare Opportunities
New York, New York, United StatesFounded 2023
Blue Owl Healthcare Opportunities focuses on investing across the capital structure in the life sciences sector, utilizing private capital solutions such as credit, royalty monetization, and equity investments. The firm's strategy is to leverage its specialized expertise and networks to identify opportunities, especially when traditional capital markets are limited.
100% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Their most common stage is series-c (50% of deals). Average disclosed round size is $219.7M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Series C
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 MapLight Therapeutics | Series D | $372.5M | Jul 2025 |
| WWindward Bio | Series A | $200M | Jan 2025 |
 Lycia Therapeutics, Inc. | Series C | $106.6M | May 2024 |
 Aviceda Therapeutics | Series C | $199.6M | — |
Top Co-Investors
Omega Funds2 shared
OrbiMed2 shared
Marshall Wace2 shared
RTW Investments2 shared
Forbion1 shared
Sanofi Ventures1 shared
Avego BioScience Capital1 shared
Enavate Sciences1 shared
Longitude Capital1 shared
Logos Capital1 shared
Catalio Capital Management1 shared
funds managed by abrdn Inc.1 shared
Digitalis Ventures1 shared
Jeito Capital1 shared
Janus Henderson Investors1 shared
Franklin Templeton1 shared
Redmile Group1 shared
Invus1 shared
Eli Lilly and Company1 shared
Last updated: 8 March 2026